Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orexo ABORXOY 35 Days Sales Outstanding is 579.24 as of Jun. 2026, which is 393% above its 10-year median of 117.51. GuruFocus rates ORXOY with a GF Score™ of 35/100 and a GF Value™ of $0.49 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 948 Drug Manufacturers companies, Orexo AB ranks worse than 96.73% on this metric.
Orexo AB's average Accounts Receivable for the
three
months ended in Jun. 2026 was $2.34 Mil. Orexo AB's Revenue for the
three
months ended in Jun. 2026 was $0.37 Mil.
Hence, Orexo AB's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 579.24.
The historical rank and industry rank for Orexo AB's Days Sales Outstanding or its related term are showing as below:
ORXOY'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 89.54 Med: 117.51 Max: 2689.77
Current: 310.68
During the past 13 years, Orexo AB's highest Days Sales Outstanding was 2689.77. The lowest was 89.54. And the median was 117.51.
ORXOY's Days Sales Outstanding is ranked worse than 96.73% of 948
companies
in the Drug Manufacturers industry
Industry Median: 71.925
vs ORXOY: 310.68
Orexo AB's Days Sales Outstanding
declined
from Jun. 2025 (3,037.74) to Jun. 2026 (579.24).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Orexo AB (OTCPK:ORXOY) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Orexo AB Days Sales Outstanding Related Terms
Orexo AB Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Orexo AB's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Orexo AB's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 579.24 mean?
Orexo AB (ORXOY) has a Days Sales Outstanding of 579.24 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Orexo AB and its competitors. This is 393% above median its historical median of 117.51. Over the past decade, Orexo AB's Days Sales Outstanding has ranged from 89.54 to 2,689.77. According to the industry distribution chart, Orexo AB ranks #917 out of 948 companies in the Drug Manufacturers industry, placing it in the top 96.7%.
Is Orexo AB's Days Sales Outstanding too high?
Orexo AB's current Days Sales Outstanding of 579.24 is 393% above median its 10-year median of 117.51. Over the past 10 years, this metric has ranged from a low of 89.54 to a high of 2,689.77. The Drug Manufacturers industry median Days Sales Outstanding is 71.93. Orexo AB's value of 579.24 is 705.3% above this industry median. Based on the distribution chart, Orexo AB ranks #917 out of 948 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orexo AB has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #917 out of 948 companies for Days Sales Outstanding. This places Orexo AB in the lower half of its industry. The industry median Days Sales Outstanding is 71.93. Orexo AB's value of 579.24 is 705.3% above this benchmark. Historically, Orexo AB's own Days Sales Outstanding has ranged from 89.54 to 2,689.77 over the past decade. While the company's 10-year median is 117.51 vs. the industry median of 71.93, Orexo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.93, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Days Sales Outstanding of 579.24 is 705.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Days Sales Outstanding is 579.24, which is 393% above median its own 10-year median of 117.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOY) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.49, compared to a current price of $1.39 — trading 183.7% above its estimated fair value. The current Days Sales Outstanding is 579.24, which is 393% above median its 10-year median of 117.51 and 705.3% above the Drug Manufacturers industry median of 71.93. Orexo AB's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Orexo AB (ORXOY), the current Days Sales Outstanding is 579.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOY) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $1.39 is trading 183.7% above its estimated GF Value™ of $0.49.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOY:
Days Sales Outstanding: 579.24 (393% above median its 10-year median of 117.51)
GF Value™: $0.49 vs. price of $1.39 (183.7% above fair value)
Industry Position: 705.3% above the Drug Manufacturers median (#917 of 948)
No single metric tells the full story. See the ORXOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
35GF Score
Get the complete analysis for ORXOY
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOY has been successfully added to your 
